Study of the possible synergistic protective effects of Melatonin and Pregabalin in Vincristine induced peripheral neuropathy Wistar Albino rats.
Chemotherapy Induced Peripheral Neuropathy (CIPN) results from some widely used chemotherapeutic agents as Vincristine (VCR). CIPN can turn so tough that a reduction in the chemotherapy dose is a must. Melatonin (an antioxidant) can be used to counteract VCR's CIPN effect on the sciatic nerve and potentiate its anticancer effect in colon cancer. In vivo and in vitro experiments were conducted in the study. The in vivo experiment included developing a CIPN Wistar Albino rat model. They were injected with VCR sulfate to induce CIPN, while Melatonin and Pregabalin were co-administered with the aim of investigating the degeneration/protection of the sciatic nerve and toxicity level. Tail Immersion Test (TIT) and histopathological analyses were done to validate the experimental model (induction of rat peripheral neurodegeneration) and examine the possible Melatonin synergistic effect. Concerning the in vitro experiment, cell viability tests in addition to apoptotic assays were conducted using HCT-116 colon cancer cell line treated with VCR, Melatonin and their combination. Liver and kidney function tests, catalase activity and malondialdehyde (MDA) levels were measured. VCR caused an elevated level of oxidation (MDA level increase) in the sciatic nerve, while Melatonin could proof its antioxidant effect through increasing catalase activity (antioxidant enzyme) with no significant toxic effect on body's functions. HCT-116 in-vitro test proved the strong cytotoxic effect of VCR and Melatonin synergism on the apoptosis level (Caspases 3 and 9 increased levels) and inhibitory concentration 50%. In conclusion, Melatonin possesses an antioxidant effect that can protect the sciatic nerve from degeneration and potentiate VCR's anticancer effect at the same time.